Go to content
UR Home

Levosimendan Efficacy and Safety

Papp, Zoltán ; Agostoni, Piergiuseppe ; Alvarez, Julian ; Bettex, Dominique ; Bouchez, Stefan ; Brito, Dulce ; Černý, Vladimir ; Comin-Colet, Josep ; Crespo-Leiro, Marisa G. ; Delgado, Juan F. ; Édes, Istvan ; Eremenko, Alexander A. ; Farmakis, Dimitrios ; Fedele, Francesco ; Fonseca, Cândida ; Fruhwald, Sonja ; Girardis, Massimo ; Guarracino, Fabio ; Harjola, Veli-Pekka ; Heringlake, Matthias ; Herpain, Antoine ; Heunks, Leo M. A. ; Husebye, Tryggve ; Ivancan, Višnja ; Karason, Kristjan ; Kaul, Sundeep ; Kivikko, Matti ; Kubica, Janek ; Masip, Josep ; Matskeplishvili, Simon ; Mebazaa, Alexandre ; Nieminen, Markku S. ; Oliva, Fabrizio ; Papp, Julius-Gyula ; Parissis, John ; Parkhomenko, Alexander ; Põder, Pentti ; Pölzl, Gerhard ; Reinecke, Alexander ; Ricksten, Sven-Erik ; Riha, Hynek ; Rudiger, Alain ; Sarapohja, Toni ; Schwinger, Robert H. G. ; Toller, Wolfgang ; Tritapepe, Luigi ; Tschöpe, Carsten ; Wikström, Gerhard ; von Lewinski, Dirk ; Vrtovec, Bojan ; Pollesello, Piero



Abstract

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons